Physician profile
Charles B Avera
NPI 1144281544
$1,734.94
in general payments reported to CMS, 2019-2025
14 companies · $581 in 2025
The $581 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.90 · 2020: $18.09 · 2021: $68.06 · 2022: $139 · 2023: $185 · 2024: $685 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $547.54 | 2024-2025 | |
| Abbvie INC. | $543.45 | 2022-2025 | Lumigan, Alphagan P |
| Alcon Vision LLC | $283.61 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Ocular Therapeutix, INC. | $122.76 | 2023-2025 | Dextenza |
| Amgen INC. | $39.19 | 2025 | Tepezza |
| Coloplast Corp | $35.12 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $32.88 | 2023 | Veritas Vision System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.98 | 2023 | |
| Aerie Pharmaceuticals, INC. | $20.26 | 2021 | |
| Bausch & Lomb Americas INC. | $18.44 | 2025 | Miebo, Vyzulta |
| Allergan, INC. | $18.09 | 2020 | |
| Rayner Intraocular Lenses Limited | $15.27 | 2024 | Omidria |
| Rxsight INC | $13.66 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Avera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.